Thymosin beta-4

Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.

Limited human evidence. Some human evidence exists, but it is small, early, indirect, or limited to a particular formulation or population.

Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.

A large preclinical literature describes actin binding, cell migration, angiogenesis, and repair responses in models. These effects are context-dependent and do not establish outcomes in people.[1]

Preclinical findings do not establish outcomes in people.

Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.

This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.

• Source/status dateJul 22, 2026

  Research only

  Thymosin beta-4 is not an FDA-approved drug. Products marketed for treatment are unapproved, and the compound should not be conflated with an undefined TB-500 product.

  Specific product form or route is not separately published in this status record.

  Open source context

The date above is the date attached to the published status record or source context. It is not necessarily the original approval date.

These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

Related means that the profiles share a topic, pathway, product context, or research question. It does not mean that they are equivalent.

• BPC-157Both appear in tissue-repair research, with different identities and limited human evidence.

PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.

1. 1

   Review of beta-thymosins

   Hannappel E. Beta-thymosins. Cellular and Molecular Life Sciences. 2007.

   Cellular and Molecular Life Sciences · Published Sep 1, 2007 · Accessed Jul 22, 2026 · Systematic review

   Open source
2. 2

   FDA warning letter: ineligible peptide drug products

   U.S. Food and Drug Administration. Warning Letter to Tailor Made Compounding LLC. April 1, 2020.

   U.S. Food and Drug Administration · Published Apr 1, 2020 · Accessed Jul 22, 2026 · Regulatory source

   Open source